Your browser doesn't support javascript.
loading
ICAM3 mediates inflammatory signaling to promote cancer cell stemness.
Shen, Wenzhi; Xie, Junling; Zhao, Shuangtao; Du, Renle; Luo, Xiaohe; He, Huiwen; Jiang, Shan; Hao, Na; Chen, Chong; Guo, Chunlei; Liu, Yanhua; Chen, Yanan; Sun, Peiqing; Yang, Shengyong; Luo, Na; Xiang, Rong; Luo, Yunping.
Afiliação
  • Shen W; Dept. of Immunology, Institute of Basic Medical Science, Chinese Academy of Medical Science, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China; International Joint Center for Biomedical Re
  • Xie J; Dept. of Immunology, Institute of Basic Medical Science, Chinese Academy of Medical Science, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China; Collaborative Innovation Center for Biothera
  • Zhao S; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China.
  • Du R; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China.
  • Luo X; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China.
  • He H; Dept. of Immunology, Institute of Basic Medical Science, Chinese Academy of Medical Science, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China; Collaborative Innovation Center for Biotherapy, School of Basic Medical Science, Chinese Academy of Medical Science and Peking U
  • Jiang S; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China.
  • Hao N; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China.
  • Chen C; Dept. of Immunology, Institute of Basic Medical Science, Chinese Academy of Medical Science, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China; Collaborative Innovation Center for Biotherapy, School of Basic Medical Science, Chinese Academy of Medical Science and Peking U
  • Guo C; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China.
  • Liu Y; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China; International Joint Center for Biomedical Research of the Ministry of Education, Tianjin 300071, China.
  • Chen Y; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China; International Joint Center for Biomedical Research of the Ministry of Education, Tianjin 300071, China.
  • Sun P; Dept. of Cancer Biology and Comprehensive Cancer Center, Wake Forest University Medical Center, Medical Blvd, Winston-Salem, NC 27157, USA.
  • Yang S; West China Hospital, Molecular Medicine Research Centre, State Key Lab Biotherapy, Sichuan University, Chengdu 610064, China.
  • Luo N; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China.
  • Xiang R; Dept. of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China; International Joint Center for Biomedical Research of the Ministry of Education, Tianjin 300071, China.
  • Luo Y; Dept. of Immunology, Institute of Basic Medical Science, Chinese Academy of Medical Science, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China; Collaborative Innovation Center for Biotherapy, School of Basic Medical Science, Chinese Academy of Medical Science and Peking U
Cancer Lett ; 422: 29-43, 2018 05 28.
Article em En | MEDLINE | ID: mdl-29477378
ABSTRACT
In this study, we present a medium throughput siRNA screen platform to identify inflammation genes that regulate cancer cell stemness. We identified several novel candidates that decrease OCT4 expression and reduce the ALDH + subpopulation both of which are characteristic of stemness. Furthermore, one of the novel candidates ICAM3 up-regulates in the ALDH + subpopulation, the side population and the developed spheres. ICAM3 knockdown reduces the side population, sphere formation and chemo-resistance in MDA-MB-231 human breast cancer cells and A549 lung cancer cells. In addition, mice bearing MDA-MB-231-shICAM3 cells develop smaller tumors and fewer lung metastases versus control. Interestingly, ICAM3 recruits and binds to Src by the YLPL motif in its intracellular domain which further activates the PI3K-AKT phosphorylation cascades. The activated p-AKT enhances SOX2 and OCT4 activity and thereby maintains cancer cell stemness. Meanwhile, the p-AKT facilitated p50 nuclear translocation/activation enhances p50 feedback and thereby promotes ICAM3 expression by binding to the ICAM3 promoter region. On this basis, Src and PI3K inhibitors suppress ICAM3-mediated signaling pathways and reduce chemo-resistance which results in tumor growth suppression in vitro and in vivo. In summary, we identify a potential CSC regulator and suggest a novel mechanism by which ICAM3 governs cancer cell stemness and inflammation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Transdução de Sinais / Antígenos CD / Moléculas de Adesão Celular / Inflamação / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Transdução de Sinais / Antígenos CD / Moléculas de Adesão Celular / Inflamação / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2018 Tipo de documento: Article